Shanghai Pharmaceuticals Holding Co. (“Shanghai Pharma”) reported first-half 2026 revenue of RMB147.47 billion, an increase of 4.15% year on year. Net profit attributable to shareholders fell 21.40% to RMB3.50 billion, weighed by lower one-off gains. Excluding non-recurring items, underlying profit grew 17.98% to RMB2.48 billion, reflecting stronger operating performance.
\n\nSegment performance remained mixed. Pharmaceutical manufacturing revenue advanced 8.44% to RMB13.19 billion, delivering profit of RMB1.34 billion, up 1.51%. Pharmaceutical distribution—the largest contributor—generated RMB134.28 billion, up 3.75%, with profit broadly flat at RMB1.79 billion. Cash generation improved sharply: net cash from operations reached RMB4.45 billion, a 349.78% surge versus the year-earlier period.
\n\nThe balance sheet stayed stable. Total assets rose 3.27% to RMB240.77 billion, while total liabilities grew 3.23% to RMB147.98 billion, leaving the asset-liability ratio essentially unchanged at 61.46%. Net gearing edged down to 22.36%. R&D spend totalled RMB1.05 billion, equal to 7.98% of manufacturing sales, supporting 61 active drug development projects.
\n\nThe board declared an interim cash dividend of RMB1.00 per 10 shares, equivalent to RMB370.84 million and representing 10.58% of first-half attributable profit. Total equity attributable to shareholders increased 3.24% during the half to RMB78.35 billion.
\n\nOperational highlights included continued expansion of the company’s innovative drug pipeline—led by BCD-085 for ankylosing spondylitis and plaque psoriasis—as well as evidence-based research progress on traditional Chinese medicine products. In distribution, contract sales (CSO) partnerships, import agency, and innovative drug services underpinned growth. The group also pressed ahead with lean manufacturing initiatives and digital supply-chain upgrades.
\n\nShanghai Pharma retained its positions in the 2026 Fortune Global 500 (No. 411) and Pharm Exec Global 50 (No. 39), underscoring its scale in China’s evolving healthcare market.
Comments